Multiple inflammatory lesions in an oncology patient
Ramon Pigem MD
Department of Dermatology, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain
Search for more papers by this authorLidia Maroñas-Jiménez MD
Department of Dermatology, 12 de Octubre University Hospital, Madrid, Spain
Search for more papers by this authorIgnasi Pau-Charles MD
Department of Dermatology, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain
Search for more papers by this authorCorresponding Author
José M. Mascaró Jr MD
Department of Dermatology, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain
Correspondence
José M. Mascaró, Jr, md
Department of Dermatology
Hospital Clínic
C/ Villarroel 170
08036 Barcelona
Spain
E-mail: [email protected]
Search for more papers by this authorRamon Pigem MD
Department of Dermatology, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain
Search for more papers by this authorLidia Maroñas-Jiménez MD
Department of Dermatology, 12 de Octubre University Hospital, Madrid, Spain
Search for more papers by this authorIgnasi Pau-Charles MD
Department of Dermatology, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain
Search for more papers by this authorCorresponding Author
José M. Mascaró Jr MD
Department of Dermatology, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain
Correspondence
José M. Mascaró, Jr, md
Department of Dermatology
Hospital Clínic
C/ Villarroel 170
08036 Barcelona
Spain
E-mail: [email protected]
Search for more papers by this author
References
- 1Pomerantz H, Hogan D, Eilers D, et al. Long-term efficacy of topical fluorouracil cream 5% for treating actinic keratosis: a randomized clinical trial. JAMA Dermatol Epub 2015; May 7. doi: 10.1001/jamadermatol.2015.0502.
- 2De Moragas JM, Gimenez-Camarasa JM. 5-fluorouracil ointment in tumors of the skin. Dermatologica 1970; 140: 65–74.
- 3Falkson G, Schulz EJ. Skin changes in patients treated with 5-fluorouracil. Br J Dermatol 1962; 74: 229–236.
- 4Remlinger KA. Cutaneous reactions to chemotherapy drugs: the art of consultation. Arch Dermatol 2003; 139: 77–81.
- 5Peramiquel L, Dalmau J, Puig L, et al. Inflammation of actinic keratosis and acral erythrodysthesia during capecitabine treatment. J Am Acad Dermatol 2006; 55: S119–S120.
- 6Mir-Bonafré JM, Cañueto J, Bravo J, et al. Improvement of actinic keratosis associated with sunitinib therapy for metastatic renal cell carcinoma. Int J Dermatol 2013; 52: 1445–1447.
- 7Al-Niami F, Lyon C. Resolving actinic keratosis: an expected side-effect of capecitabine therapy. Clin Exp Dermatol 2012; 37: 68–69.
- 8Krathen M, Treat J, James WD. Capecitabine induced inflammation of actinic keratosis. Dermatol Online J 2007; 13: 13.
- 9Serrão VV, Feio AB. Inflammation of actinic keratosis with capecitabine therapy for colon cancer. Eur J Dermatol 2008; 18: 200.
- 10Chambers CJ, Liu H, White CR, et al. Eruptive purpuric papules on the arms; a case of chemotherapy-induced inflammation of actinic keratoses and review of the literature. Dermatol Online J 2014; 20: 21246.
- 11Chun YS, Chang SN, Oh D, et al. A case of cutaneous reaction to chemotherapeutic agents showing epidermal dysmaturation. J Am Acad Dermatol 2000; 43: 358–360.